Helsinn Group Announces FDA approval of IV Formulation of Akynzeo for Chemotherapy Induced Nausea and Vomiting Configure

Helsinn Group Announces FDA approval of IV Formulation of Akynzeo for Chemotherapy Induced Nausea and Vomiting Configure

Source: 
CP Wire
snippet: 

Helsinn Group announced on 4/20/18 that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of Akynzeo (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy induced nausea and vomiting (CINV).